Allergies News and Research

Latest Allergies News and Research

Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program

Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.

6 Jan 2009

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers.

6 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Final FDA approval for generic version of antiretroviral Zerit capsules

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. Food and Drug Administration (FDA) on December 29, for its Abbreviated New Drug Application (ANDA) for Stavudine Capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.

1 Jan 2009

Antifungal medication could provide asthma relief for 150,000 UK sufferers

Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found.

From The University of Manchester 30 Dec 2008

Warning about severe allergic reactions to recalled cold and flu tablets

The Therapeutic Goods Administration (TGA) have recalled two types of cold and flu tablets following reports of a number of allergic and anaphylactic reactions.

22 Dec 2008

Adults with asthma at increased risk of serious pneumococcal disease

Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia.

22 Dec 2008

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

GlaxoSmithKline (GSK) is prepared to respond to public health needs for Relenza (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC).

21 Dec 2008

Battlefield acupuncture

Medical acupuncture, which is acupuncture performed by a licensed physician trained at a conventional medical school, is being used increasingly for pain control.

18 Dec 2008

Preventing food allergies in children - a change of strategy?

According to the Centers for Disease Control and Prevention (CDC) in the United States in 2007 around 3 million children under 18 had food allergies - a rise of 18% since 1997.

17 Dec 2008

Expert says gross over-reaction to peanuts to blame for 'nut hysteria'

A Professor at Harvard Medical School suggests many people today are over-reacting to the threat of peanut allergies in children.

17 Dec 2008

Bolder BioTechnology awarded NIH grant to continue development of growth hormone product

Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH).

16 Dec 2008

Allergic rhinitis not associated with snoring or daytime sleepiness

Allergic rhinitis does not appear to be associated with snoring or daytime sleepiness, but individuals with obstructed nasal passages are likely to experience both regardless of whether they have allergies, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery.

15 Dec 2008

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs).

12 Dec 2008

Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans

Vical Incorporated has announced that the company's Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial.

11 Dec 2008

New class of anti-inflammatory drugs

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices.

10 Dec 2008

DNA vaccine for SARS achieves neutralizing responses in first U.S. human trial

Vical Incorporated (NASDAQ:VICL) today announced that results from a Phase I clinical trial of a DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the National Institutes of Health (NIH) and published in the November 25 issue of Vaccine(1), demonstrated that the vaccine was well-tolerated, and induced neutralizing antibody responses in 80% of the vaccinees and T-cell immune responses in all vaccinees.

10 Dec 2008

Lupin allergy in children

During her doctoral work, Lise Holden developed a method of identifying lupin protein in food products. She also investigated the incidence of lupin allergy among children with food allergy and studied the proteins in lupin responsible for allergy production.

8 Dec 2008

New approaches to prevent blood clots

The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.

8 Dec 2008